Daniel Lage is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 80 publications with 1,164 citations (h-index 17); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
212-639-2000Provider last certified this registry record 27 Oct 2025.
Clinical trials
- PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention
Sponsor: Massachusetts General Hospital
- Care Transition Intervention for Hospitalized Patients With Advanced Cancer
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.2%Cytochrome P450 17A1 Inhibitor31.8%Abiraterone Acetate100%Part D≥12 patientsGonadotropin Releasing Hormone Receptor Antagonist22.9%Orgovyx100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
26.8%Corticosteroid26.8%Prednisone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Journal of Clinical Oncology
2026 - Paired Nectin4 expression analysis pre and post enfortumab vedotin and pembrolizumab in urothelial carcinoma.
Journal of Clinical Oncology
2026 - Continuum: A Postdischarge Supportive Care Intervention for Hospitalized Patients With Advanced Cancer
Journal of Pain and Symptom Management
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”